Heart valve with reduced calcification
US10966822B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 21, 2019 |
| Grant date | Apr 6, 2021 |
| Priority date | — |
| Expiry date | Jan 21, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2430/20
- WIPO fieldMedical technology
- WIPO sectorInstruments
Abstract
A method for manufacturing a heart valve using bioprosthetic tissue that exhibits reduced in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.